STATUTORY RULES
1968 No
_______
REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1967.
I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953-1967.
Dated this twenty-fourth day of July, 1968.
CASEY
Governor-General.
By His Excellency’s Command,
(SGD.) A. J. FORBES
Minister of State for Health.
________
Amendments of the National Health (Pharmaceutical Benefits) Regulations†
Commencement.
1. These Regulations shall come into operation on the first day of August, 1968.
First Schedule.
2.—(1.) The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended by omitting items 66, 79, 98, 182, 400, 416 and 417.
(2.) The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—
(a) by inserting after item 235 the following item:—
“ 235a. Methicillin Sodium ”; and
(b) by inserting after item 316 the following item:—
“ 316a. Prednisolone Trimethylacetate Injection ”.
Second Schedule.
3.—(1.) The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended by inserting after item 33 the following items:—
“ 33a | Dexamethasone...................... | Dexamethasone with Framycetin Sulphate and Gramicidin |
33b | Dexamethasone Metasulphobenzoate | Dexamethasone Metasulphobenzoate with Framycetin Sulphate and Gramicidin”. |
(2.) The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended by omitting item 63 and inserting in its stead the following item:—
“ 63 | Hexachlorophane, B.P.................. | Hexachlorophane B.P. with Entsufon |
|
| Hexachlorophane B.P. with Terric |
|
| Hexachlorophane B.P. in Soap Solution |
|
| Hexachlorophane B.P. with Chloroxylenol ”. |
Third Schedule.
4. The Third Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the First Schedule to these Regulations.
Fifth Schedule.
5. The Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the Second Schedule to these Regulations.
_______________________________________________________________________________________
Notified in the Commonwealth Gazette on 1968.
† Statutory Rules 1960, No. 17 as amended to date. For previous amendments of the National Health (Pharmaceutical Benefits) Regulations, see footnote to Statutory Rules 1968, No. 44, and see also Statutory Rules 1968, No. 44.
18279/68—PRICE 10c 10/12.7.1968
THE SCHEDULES
____
Regulation 4.
FIRST SCHEDULE
Amendments of the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations
1. Omit item 1, insert:—
“1. Acepifylline”
“1a. Acetazolamide Sodium”.
2. After item 14 insert:—
“14a. Aloxiprin”.
3. After item 85 insert:—
“85a. Chloroxylenol”.
4. After item 94 insert:—
“94a. Coal Tar Solution Strong B.P.C.”.
5. After item 105 insert:—
“105a. Debrisoquine”.
6. After item 109 insert:—
“109a. Dexamethasone Metasulphobenzoate”.
7. After item 137 insert:—
“137a. Ethchlorvynol”.
8. After item 168a insert:—
“168b. Haloperidol”.
9. After item 241 insert:—
“241a. Nitrazepam”.
10. After item 250 insert:—
“250a. Orphenadrine Citrate”.
11. After item 255 insert:—
“255a. Oxymetholone”.
12. Omit from item 299 “Hemisuccinate”, insert “Succinate”.
13. After item 304 insert:—
“304a. Protriptyline Hydrochloride”.
14. Omit item 367.
15. After item 373 insert:—
“373a. Tiemonium Iodide”.
16. After item 379 insert:—
“379a. Triacetyloleandomycin”.
__________
SECOND SCHEDULE Regulation 5.
Amendments of the Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations
1 After item 5 insert:—
“ 5a | Aloxiprin | Any disease or condition in a pensioner”. |
2. Omit from item 6 “ (2) Amino Acids ” (in the second column).
3. Omit item 10, insert:—
“ 10 | (1) Ampicillin Capsules, B.P....... | With the written authority of the Director-General— Gram-negative infections in pregnant women Infections in children, in which penicillin and sulphonamides are not effective Infections where positive bacteriological evidence confirms that ampicillin is an appropriate therapeutic agent and the Director-General is satisfied that it is the most appropriate therapeutic agent in all the circumstances of the case Acute infections threatening the life of a patient where clinical evidence shows that ampicillin is an appropriate therapeutic agent and the Director-General is satisfied that it is the most appropriate therapeutic agent in all the circumstances of the case Chronic bronchitis complicated by emphysema where other therapeutic agents have failed ”. |
| (2) Ampicillin Injections, Tablets and Suspension | |
|
|
SECOND SCHEDULE—continued
4. Insert in item 16, after “ Prednisolone Tablets ” (in the third column), “, B.P.”.
5. Omit item 22.
6. Insert in item 29, after “ Capsule ” (in the third column), “, B.P.”.
7. Insert in item 33, after “ Capsules ” (in the third column), “, B.P.”.
8. Item 38.—
(a) insert before “ Hypsarrhythmia ” (in the third column)—
“ Acute exacerbations of multiple sclerosis
Acute phase of Bell’s palsy ”; and
(b) insert after “Cortisone Injection” (in the third column), “, B.P.”.
9. Omit items 40 to 43 (inclusive), insert:—
“ 40 | Cortisone Tablets, B.P....... | With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection, B.P. |
“ 41 | Cyanocobalamin Injection, B.P. | Established megalocytic anaemia Neuroblastoma Sub-acute combined degeneration of the cord Treatment in post-gastrectomy |
“ 41a | Cymogran............... | With the written authority of the Director-General, phenylketonuria |
“ 42 | (1) Cycloserine Tablets, B.P... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
| (2) Cycloserine Capsules, B.P.. | |
“ 42a | (1) Demethylchlortetracycline Capsules, B.P. | A disease or condition specified in this column in relation to Chlortetracycline Capsules B.P., except herpes zoster opthalmicus |
| ||
| (2) Demethylchlortetracycline Hydrochloride Oral Paediatric Drops and Oral Suspension | |
|
|
|
“ 43 | Demethylchlortetracycline Hydrochloride with Nystatin | Any disease or condition specified in this column in relation to Oxytetracycline Hydrochloride with a buffering agent and Nystatin ”. |
10. Insert in item 47, after “ Prednisolone Tablets ” (in the third column), “, B.P.”.
11. After item 57 insert:—
“ 57a | Dimethicone Creams......... | Use with surgical appliances ”. |
12. Insert in item 60, after “ Capsules ” (in the third column), “, B.P.”.
13. After item 80 insert:—
“ 80a | Haloperidol............. | Any disease or condition in a pensioner Any disease or condition in a patient receiving treatment in or at an approved hospital With the written authority of the Director-General— Radiation sickness Huntington’s chorea Late-stage malignancy The treatment of a mental disorder in a person who has been discharged from an approved hospital at which ho received treatment for a mental disorder and who is living in a place remote from an approved hospital The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that the person received treatment at that hospital and may require further treatment with Haloperidol ”. |
SECOND SCHEDULE—continued
14. Omit item 82, insert:—
“ 82 | (1) Hexachlorophane with Chloroxylenol | Any disease or condition in patient receiving treatment in or at an approved hospital ”. |
| (2) Hexachlorophane with Entsufon |
|
| (3) Hexachlorophane with Lissapol |
|
| (4) Hexachlorophane in Soap Solution |
|
15. Insert in item 83, after “ Injection ” (in the third column), “, B.P.”.
16. Omit from item 96 “ Myxoedema coma ” (in the third column).
17. Omit from item 99 “ Endometrial carcinoma ” (in the third column), insert “ Adenocarcinoma of the uterus (endometrial carcinoma) ”.
18. Omit item 100, insert:—
“ 100 | Medroxyprogesterone Acetate Tablets 100 mg. | Adenocarcinoma of the body of the uterus Hypernephroma |
“ 100a | Medroxyprogesterone Acetate Injections | Adenocarcinoma of the uterus (endometrial carcinoma) Hypernephroma Progesterone deficiency proven by hormonal assay of lateral wall smear ”. |
|
| |
|
|
19. Insert in item 104, after “ Capsules ” (in the third column), “, B.P.”.
20. Omit item 106, insert:—
“ 106 | Methicillin Injection, B.P....... | Proven or suspected staphylococcal septicaemia ” |
21. Omit from item 114 “ With the written authority of the Director-General, urinary tract infections ” (in the third column), insert “ Urinary tract infections in which sulphonamides are not effective ”.
22. After item 116 insert:—
“ 116a | Natamycin................ | Monilia infections ”. |
23. After item 120 insert:—
“ 120a | Nitrazepam............... | Myoclonic epilepsy in children ”. |
24. Omit from item 126 “(2) Orciprenaline Sulphate Solution for Inhalation” (in the second column).
25. After item 128 insert;—
“ 128a | Oxymetholone............. | With the written authority of the Director-General— Aplastic anaemia Primary refractory anaemias ”. |
26. Insert in item 129, after “ Capsules ” (in the third column), “, B.P.”.
27. Insert in item 130, after “ Capsules ” (in the third column), “, B.P.”.
28. Omit item 135, insert:—
“ 135 | Paramethasone Acetate .. | With the written authority of the Director-General— Acute phase of herpes zoster A disease or condition specified in this column in relation to Cortisone Injection, B.P.”. |
SECOND SCHEDULE—continued
29. After item 143 insert:—
“ 143a | (1) Phenylbutazone Suppositories (2) Phenylbutazone Injection........ | For the treatment of the following conditions in persons who cannot tolerate Phenylbutazone Tablets, B.P. and Phenylbutazone Capsules:— Acute attacks of gout Ankylosing spondylitis Psoriatic arthritis Reiter’s syndrome Rheumatoid arthritis or osteoarthritis not responding to salicylates ”. |
|
| |
|
|
30. Omit item 149, insert:—
“ 149 | Prednisolone Tablets, B.P. .. | With the written authority of the Director-General— Acute exophthalmic ophthalmoplegia Acute heart block complicating myocardial Infarction Acute phase of herpes zoster Benign intracranial hypertension Cerebral oedema Cerebral tumors Encephalitis Interstitial keratitis due to syphilis or vernal conjunctivitis Malignancy treatment in conjunction with radiotherapy or chemotherapy Malignant exophthalmos Meningitis Nodular non-suppurative panniculitis (Christian-Weber disease) Oedema of the spinal cord following trauma or infection A disease or condition specified in this column in relation to Cortisone Injection, B.P. except total adrenalectomy, Addison’s disease or adrenocortical hypoplasia ”. |
|
| |
|
| |
|
| |
|
|
31. Omit item 150, insert:—
“ 150 | Prednisolone Methyl Acetate Injection | Intra-articular use ”. |
32. Omit item 151, insert:—
“ 151 | (1) Prednisolone Acetate Injection (2) Prednisolone Tertiary Butyl | Acetate Injection Intra-articular use ”. |
33. Omit from item 153 “ Hemisuccinate ” (in the second column), insert “ Succinate ”.
34. Insert in item 154, after “ Tablets ” (in the third column), “ B.P.”.
35. Omit from item 157 “ (2) Pyrazinamide ” (in the second column).
36. After item 157 insert:—
“ 157a | Protriptyline Hydrochloride .. | Any disease or condition in a pensioner Any disease or condition in a patient receiving treatment in or at an approved hospital With the written authority of the Director-General— The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Protriptyline Hydrochloride |
|
| |
“ 157b | Pyrazinamide .. .. | Any disease or condition in a patient receiving treatment in or at an approved hospital ”. |
SECOND SCHEDULE—continued
37. Omit from item 177 “ Patients known to be sensitive to horse serum ” (in the third column), insert “ Patients who have previously received an injection of equine serum ”.
38. Insert in item 180, after “ Capsules ” (in the third column), “, B.P.”.
39. Omit from item 184:—
“ Thioridazine
Thioridazine Hydrochloride ”
(in the third column), insert—
“ Thioridazine
Thioridazine Tablets, B.P.”.
40. After item 188 insert:—
“ 188a | Triacetyloleandomycin........ | Brucellosis Intestinal amoebiasis Leptospirosis Lymphogranuloma venereum Mycoplasma pneumoniae (Eaton’s Agent) Psittacosis Rickettsial infections Staphylococcal septicaemia or staphylococcal pneumonia Any bacterial infections or spirochaetal infection or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur ”. |
________________
By Authority: A. J. Arthur, Commonwealth Government Printer, Canberra